- Conditions
- Pigment Epithelial Detachment
- Interventions
- iSONEP (sonepcizumab/LT1009)
- Drug
- Lead sponsor
- Lpath, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 5
- States / cities
- Winter Haven, Florida • West Mifflin, Pennsylvania • West Columbia, South Carolina + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age-related Macular Degeneration
- Interventions
- RetnaGene AMD LDT
- Device
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
- Conditions
- Age Related Macular Degeneration
- Interventions
- adaptive optics AO-OCT/AF instrument
- Diagnostic Test
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD, Macular Degeneration, Age-related, 10, Eye Diseases, Retinal Degeneration, Retinal Diseases
- Interventions
- X-82, Anti-VEGF, Placebo
- Drug
- Lead sponsor
- Tyrogenex
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Beverly Hills, California • Huntington Beach, California + 32 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- Longvida curcumin, placebo
- Drug · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Central Visual Impairment, Macular Degeneration
- Interventions
- Training visual sensitivity, Combination training
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
- Conditions
- Macular Degeneration, Central Visual Impairment
- Interventions
- Personalised Remapping Training, RSVP personalized remappi, Reading text in the wild with remapping
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Edina, Minnesota
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- RTH258
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 3
- States / cities
- Altamonte Springs, Florida • Pensacola, Florida • Richmond, Virginia
- Conditions
- AMD, Age- Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Durham, North Carolina
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Interventions
- Aflibercept (2.0 mg)
- Biological
- Lead sponsor
- Exegenesis Bio
- Industry
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Reno, Nevada • Erie, Pennsylvania
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- fluocinolone acetonide (Retisert Implant, Bausch and Lomb)
- Device
- Lead sponsor
- Glenn Jaffe
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
- Interventions
- Not listed
- Lead sponsor
- Optos, PLC
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 3
- States / cities
- Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas
- Conditions
- Age-related Macular Degeneration
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
- Conditions
- Macular Edema, Macular Degeneration
- Interventions
- RHMS-RTM, SD-OCT
- Device · Diagnostic Test
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Maculopathy, Age-Related
- Interventions
- Anecortave Acetate 15 mg, Triamcinolone Acetate 4 mg, Photodynamic Therapy with Verteporfin, Thermal Laser
- Drug · Procedure
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 60 Years to 95 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
- Interventions
- D-4517.2
- Drug
- Lead sponsor
- Ashvattha Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Lemont, Illinois • Indianapolis, Indiana + 12 more
- Conditions
- Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- bevacizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania
- Conditions
- Wet Age Related Macular Degeneration, wAMD
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 78
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 69 more
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration (nAMD)
- Interventions
- EXG102-031
- Biological
- Lead sponsor
- Exegenesis Bio
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Reno, Nevada • Erie, Pennsylvania
- Conditions
- Age Related Macular Degeneration, AMD, CNV
- Interventions
- Efalizumab, Ranibizumab
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Exudative Macular Degeneration
- Interventions
- X-82 oral, ranibizumab (Lucentis)
- Drug
- Lead sponsor
- Tyrogenex
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • New London, Connecticut • Baltimore, Maryland + 2 more